DURELOPDI Trademark

Trademark Overview


On Wednesday, April 1, 2020, a trademark application was filed for DURELOPDI with the United States Patent and Trademark Office. The USPTO has given the DURELOPDI trademark a serial number of 88856523. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 1, 2021. This trademark is owned by Bristol-Myers Squibb Company. The DURELOPDI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy; cells for medical or clinical...
durelopdi

General Information


Serial Number88856523
Word MarkDURELOPDI
Filing DateWednesday, April 1, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 1, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 2, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy; cells for medical or clinical use; diagnostic kits consisting primarily of cells for medical or clinical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 9, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Monday, November 1, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 1, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, March 30, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 2, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 2, 2021PUBLISHED FOR OPPOSITION
Wednesday, January 13, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, December 23, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 23, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 22, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 22, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, June 22, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, June 22, 2020NON-FINAL ACTION E-MAILED
Monday, June 22, 2020NON-FINAL ACTION WRITTEN
Monday, June 22, 2020ASSIGNED TO EXAMINER
Thursday, April 9, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, April 4, 2020NEW APPLICATION ENTERED IN TRAM